FATE
FATE
NASDAQ · Biotechnology

Fate Therapeutics Inc

$1.28
-0.06 (-4.48%)
As of Nov 14, 10:38 PM ET ·
Analyst Consensus
Buy
18
Analysts
High
Coverage
Buy 11 61%
Hold 7 39%
Sell 0 0%
Price Target
Analyst Price Target +349.2% upside
Low Target $4.43
Average Target $5.75
High Target $6.69
Current Price $1.28
Current
$1.28
Target
$5.75
$4.43 $5.75 avg $6.69
Scenario Analysis
Bear Case
$4.43
246.1%
Low target
Base Case
$5.75
+349.2%
Avg target
Bull Case
$6.69
+422.7%
High target
Risk/Reward
1.7x
Balanced
Price in Context
52-Week High
$3.23
-60.4% from high
52-Week Low
$0.95
+34.7% from low
Target vs 52W High
$5.75
+78.0% vs high
Peer Consensus — Biotechnology
Stock Consensus Analysts Buy % Target Upside
ABBV
Abbvie Inc
Strong Buy 38 82% $257.58 -12.7%
AMGN
Amgen Inc
Hold 42 43% $190.87 -59.0%
GILD
Gilead Sciences Inc
Strong Buy 36 83% $362.68 +115.8%
VRTX
Vertex Pharmaceuticals Inc
Strong Buy 39 82% $438.34 -18.6%
REGN
Regeneron Pharmaceuticals
Buy 36 72% $76.80 -92.0%
MRNA
Moderna Inc
Hold 31 32% $149.45 -33.1%
NTRA
Natera Inc
Strong Buy 31 90% $142.91 -55.2%
RVMD
Revolution Medicines Inc
Strong Buy 31 94% $114.11 -33.8%